412 results on '"Giannetti, Nadia"'
Search Results
2. Mobile Health Fitness Interventions: Impact of Features on Routine Use and Data Sharing Acceptability
3. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
4. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19
5. Evaluating the Reparative Potential of Secretome from Patient-Derived Induced Pluripotent Stem Cells during Ischemia–Reperfusion Injury in Human Cardiomyocytes.
6. Clinical Phenotypes in Patients With Type 2 Diabetes Mellitus: Characteristics, Cardiovascular Outcomes and Treatment Strategies
7. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
8. Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation
9. Abstract 9920: Utilizing Synchronous Healthcare Delivery to Optimize the Use of Guideline Directed Medical Therapies in Patients With Type 2 Diabetes: Results From the DECIDE-CV Clinic
10. Patient-Centered Approach to Heart Failure Management: Transforming Care Delivery
11. Insights Into Myocardial Oxygenation and Cardiovascular Magnetic Resonance Tissue Biomarkers in Heart Failure With Preserved Ejection Fraction
12. Cost-effectiveness of coronary artery bypass grafting plus mitral valve repair versus coronary artery bypass grafting alone for moderate ischemic mitral regurgitation
13. Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement on Heart Transplantation: Patient Eligibility, Selection, and Post-Transplantation Care
14. CCS/CHFS Heart Failure Guidelines: Clinical Trial Update on Functional Mitral Regurgitation, SGLT2 Inhibitors, ARNI in HFpEF, and Tafamidis in Amyloidosis
15. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial
16. Pacemaker Implantation After Mitral Valve Surgery With Atrial Fibrillation Ablation
17. Spontaneous coronary artery dissection: a difficult journey from emergency coronary artery bypass grafting to left ventricular assist device.
18. Recurrent Giant Cell Myocarditis Following Orthotopic Heart Transplant Resulting in Urgent Redo Orthotopic Heart Transplantation: A Case Report
19. Sodium-Glucose Cotransporter 2 Inhibitor Among Patients With Cancer Therapy–Induced Left Ventricular Dysfunction
20. Predicting 1-Year Mortality in Outpatients With Heart Failure With Reduced Left Ventricular Ejection Fraction: Do Empiric Models Outperform Physician Intuitive Estimates? A Multicenter Cohort Study
21. 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure
22. Abstract 15518: Impact of Menopause on Cardiovascular Risk Factors Among Women Without Cardiovascular Disease: Insights From the CARTaGENE Study
23. Comparison of Questionnaire and Performance‐Based Physical Frailty Scales to Predict Survival and Health‐Related Quality of Life in Patients With Heart Failure
24. Muscle Mass and Mortality After Cardiac Transplantation
25. Measuring Single-Cell Calcium Dynamics Using a Myofilament-Localized Optical Biosensor in hiPSC-CMs Derived from DCM Patients.
26. The 2014 Canadian Cardiovascular Society Heart Failure Management Guidelines Focus Update: Anemia, Biomarkers, and Recent Therapeutic Trial Implications
27. Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction
28. Timing of Statistical Benefit of Mineralocorticoid Receptor Antagonists Among Patients With Heart Failure and Post-Myocardial Infarction
29. Effective use of genetically-encoded optical biosensors for profiling signalling signatures in iPSC-CMs derived from idiopathic dilated cardiomyopathy patients
30. Mobile Health Fitness Applications: A Quantitative Analysis of Features and Barriers to Routine Use and Data Sharing Acceptability (Preprint)
31. Echocardiographic Diagnosis of Acute Allograft Rejection
32. Physiological and perceived health effects from daily changes in air pollution and weather among persons with heart failure: A panel study
33. Clinical Prediction Models for Heart Failure Hospitalization in Type 2 Diabetes: A Systematic Review and Meta‐Analysis
34. Heat Awareness and Response among Montreal Residents with Chronic Cardiac and Pulmonary Disease
35. Outcomes for Women and Men Who Attend a Heart Failure Clinic: Results of a 12-Month Longitudinal Study
36. The 2011 Canadian Cardiovascular Society Heart Failure Management Guidelines Update: Focus on Sleep Apnea, Renal Dysfunction, Mechanical Circulatory Support, and Palliative Care
37. Severity at Entry to Specialized Heart Failure Clinics: Discrepancies Between Health-Related Quality of Life and Function in Men and Women
38. Risk for non-home discharge following surgery for ischemic mitral valve disease
39. The ACEi switchback study: P1014
40. The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs
41. Abstract 9009: Management of Renin-Angiotensin-Aldosterone System Blockade in Patients Admitted in Hospital With Confirmed Coronavirus Disease (COVID-19) Infection: The McGill RAAS-COVID-19 Randomized Controlled Trial
42. Empagliflozin in Heart Failure with a Preserved Ejection Fraction
43. Factors related to time to admission to specialized multidisciplinary clinics in patients with congestive heart failure
44. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: Diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials
45. Voice-based screening for SARS-CoV-2 exposure in cardiovascular clinics
46. Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial
47. Empagliflozin in Heart Failure with a Preserved Ejection Fraction
48. Percent Predicted Value for the 6-Minute Walk Test: Using Norm-Referenced Equations to Characterize Severity in Persons With CHF
49. Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies
50. Improvements in myocardial perfusion observed in patients supported with the C-Pulse counterpulsation device: P260
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.